Navigation Links
CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced preliminary results of its randomized, blinded, placebo-controlled clinical trial of CRx-150 in patients with rheumatoid arthritis (RA). The trial compared CRx-150 plus a disease-modifying anti-rheumatic drug (DMARD) to placebo plus DMARD (control) in subjects with active RA. In the preliminary analysis of this trial, CRx-150 demonstrated statistically significant effects on DAS28 and pain, a trend on ACR20 and no effect on CRP. -0-
Measure       Regimen     ITT Population    PP Population

------------------------------------------------------------

DAS28(a)          CRx-150   -0.51 (p=0.05)    -0.73 (p=0.07)

------------------------------------------------------------

                  Placebo           -0.05             -0.11

------------------------------------------------------------

ACR20             CRx-150     27% (p=0.13)      37% (p=0.08)

------------------------------------------------------------

                  Placebo              11%               13%

------------------------------------------------------------

CRP(a)            CRx-150       +0.25mg/L           -0.5mg/L

                                  (p=0.34)          (p=0.48)

------------------------------------------------------------

                  Placebo        -0.25mg/L          -0.2mg/L

------------------------------------------------------------

(a) Data provided are median change from baseline to day 42.

For CRx-150 treated subjects, median baseline pain as measured on a visual analogue scale (VAS), went from 63.0mm to 37.0mm at day 42, with a median change of -11.5mm, whereas placebo went from 64.5mm at baseline to 59.5mm at day 42, with a median change of -2.0mm (p=0.04).

CRx-150 was generally well tolerated. The most common adverse events in the CRx-150-treated group included headache,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
2. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
3. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
4. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
5. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. PromegaExpress Expands Easy Access to Products with New Cabinet
11. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 1, 2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising ... novel investigational mda-7/IL-24 tumor,suppressor agent, in patients with ... were presented today at the,annual meeting of the ... 22-patient trial, INGN 241 induced killing in all ...
... Inc.,(TSX: TLN) announced today that preliminary data from ... cancer,patients was published in abstract form as part ... Meeting in Chicago,Illinois. In the Phase I dose ... two ovarian, one duodenal and one,glioma), that had ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... ... a one and a half hour massage , ... Scottsdale, AZ (PRWEB) March 25, 2010 -- As tax day draws near, stress levels ... anxiety that the tax man bring. Enjoy $15 dollars off the retail price of an hour ...
... ... care documentation for Military Health System personnel across the Department of Defense Enterprise ... Scottsdale, AZ ... workflow solutions, has been chosen to supply clinical workflow technology to the Department of ...
... ... technology can transform the way utilities can deliver power to customers," said President & ... ... have discovered that smart grid will change every aspect of their business -- from ...
... adults, a generally healthy population, are increasingly flocking to ... treatment. Young adults remain the most likely age group ... during this pivotal transition period between adolescence and adulthood. ... care in the ED nearly twice as much ...
... The ... low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according ... ... an unusual type of fracture of the femur, or the thigh bone, is very low in ...
... one factor, researchers say , WEDNESDAY, March 24 (HealthDay News) ... pneumonia fare better in hospitals that see more of these ... study finds. , However, once the number of these patients ... of the size of the hospital, the researchers say. , ...
Cached Medicine News:Health News:Massage Envy Offers Tax Relief for Arizona Residents 2Health News:Carefx to Provide Clinical Workflow Solutions for Military Health System 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 3Health News:Transition into adult health care is a rocky road for 20 somethings 2Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 2Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 3Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 4Health News:Fewer Deaths in Larger, Busier Hospitals 2Health News:Fewer Deaths in Larger, Busier Hospitals 3
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
...
Medicine Products: